Loading…
rxmedkart.com sold unapproved and misbranded drug products through its website that claimed to mitigate, prevent, treat, diagnose, or cure COVID-19, as well as other diseases like strongyloidiasis and lymphatic filariasis, in violation of sections 505(a) and 502 of the Federal Food, Drug, and Cosmetic Act. The company failed to obtain FDA approval for these new drugs before offering them for sale to U.S. consumers over the internet, bypassing required regulatory safeguards that ensure drug safety and effectiveness. This enforcement action was issued during the COVID-19 public health emergency declared in January 2020, when the FDA prioritized removing unauthorized products making pandemic-related health claims from the marketplace.